Market Overview

Isis Reports in Phase 2 Study, Patients Treated With Isis-PTP1BRX Achieved Statistically Significant Reductions in Body Weight, Hemoglobin A1C

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News Press Releases

 

Related Articles (ISIS)

Partner Center